REG - Futura Medical PLC - Share price movement

Futura MedicalAnnouncement

Yesterday 11:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250711:nRSK7643Qa&default-theme=true

RNS Number : 7643Q  Futura Medical PLC  11 July 2025

Futura Medical plc

 

("Futura" or the "Group")

 

Share price movement

 

The Board of Futura Medical plc (AIM: FUM), the consumer healthcare Group
behind Eroxon®, that specialises in the development and global
commercialisation of innovative and clinically proven sexual health products,
notes the recent increase in the Company's share price and, save for board
changes and the proposed appointment of Alex Duggan as Interim CEO (subject to
completion of due diligence) announced on the 8 July, the  board advises that
it knows of no reason for this rise.

 

 

Contacts:

 

 Futura Medical plc             Angela Hildreth                                         investor.relations@futuramedical.com

                                                       (mailto:Investor.relations@futuramedical.com)
                                Finance Director and COO

                                                       +44 (0)1483 685 670

                                                                                      www.futuramedical.com (http://www.futuramedical.com/)

 Panmure Liberum                Emma Earl, Will Goode, Mark Rogers (Corporate Finance)  +44 (0)20 3100 2000

 Nominated Adviser              Rupert Dearden (Corporate Broking)

 and Broker

 Alma Strategic Communications  Rebecca Sanders-Hewett                                  +44 (0)20 3405 0205

                                Sam Modlin                                              futura@almastrategic.com

                                Will Ellis Hancock

 

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon(®) and products WSD4000 and
Eroxon(®) Intense. Our core strength lies in our research, development and
commercialisation of topically delivered gel formulations in sexual health
products.

 

Sexual health issues are prevalent in both men and women. ED impacts 1 in 5
men globally across all adult age brackets, with approximately half of all men
over 40 experiencing ED and 25% of all new diagnoses being in men under 40.
Around 60% of women experience at least one symptom of sexual dysfunction, and
only one in four women seek professional help, and remain chronically
underserved.

 

Eroxon(®), Futura's clinically proven lead product, has been developed for
the treatment of ED. The highly differentiated product, which is the only
topical gel treatment for ED available over the counter and helps men get an
erection in ten minutes, addresses significant unmet needs in the ED market.
Eroxon(®) has been nominated for and won a number of healthcare industry
awards.

 

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  SPMGPUPUMUPAGUG